High nigral iron deposition in LRRK2 and Parkin mutation carriers using R2* relaxometry

Movement Disorders

Volumn 30, Issue 8, 2015, Pages 1077-1084

  Pyatigorskaya, Nadya ^a,b   Sharman, Michael ^a   Corvol, Jean Christophe ^a,b,c   Valabregue, Romain ^a,c   Yahia Cherif, Lydia ^a,b,c   Poupon, Fabrice ^d   Cormier Dequaire, Florence ^a,b,c   Siebner, Hartwig ^e   Klebe, Stephan ^a,b,c,f   Vidailhet, Marie ^b,c   Brice, Alexis ^a,b,c   Lehéricy, Stephane ^a,b,c  

^a INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d DIF   (France)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

^f UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

LRRK2; MRI; Parkin; Parkinson's disease; relaxometry

Indexed keywords

LEUCINE RICH REPEAT KINASE 2; PARKIN; IRON; LRRK2 PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE; UBIQUITIN PROTEIN LIGASE;

ADULT; AGED; ARTICLE; BASAL GANGLION; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DIFFUSION WEIGHTED IMAGING; FEMALE; GENE MUTATION; GLOBUS PALLIDUS; HUMAN; IMAGE ANALYSIS; IRON STORAGE; MALE; NIGRONEOSTRIATAL SYSTEM; NUCLEAR MAGNETIC RESONANCE SCANNER; PARKINSON DISEASE; PRIORITY JOURNAL; SUBSTANTIA NIGRA; THALAMUS; GENETICS; HETEROZYGOTE; METABOLISM; MIDDLE AGED; MUTATION; NEOSTRIATUM; NUCLEAR MAGNETIC RESONANCE IMAGING; PROCEDURES;

ADULT; AGED; FEMALE; GLOBUS PALLIDUS; HETEROZYGOTE; HUMANS; IRON; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MUTATION; NEOSTRIATUM; PARKINSON DISEASE; PROTEIN-SERINE-THREONINE KINASES; SUBSTANTIA NIGRA; THALAMUS; UBIQUITIN-PROTEIN LIGASES;

EID: 84930077320     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.26218     Document Type: Article

References (39)

1. Lesage S, Brice A. Role of mendelian genes in “sporadic” Parkinson's disease. Parkinsonism Relat Disord 2012;18(Suppl 1):S66-S70.
2. Zabetian CP, Hutter CM, Yearout D, et al. LRRK2 G2019S in families with Parkinson disease who originated from Europe and the Middle East: evidence of two distinct founding events beginning two millennia ago. Am J Hum Genet 2006;79:752-758.
3. Troiano AR, Elbaz A, Lohmann E, et al. Low disease risk in relatives of north african lrrk2 Parkinson disease patients. Neurology 2010;75:1118-1119.
4. Lucking CB, Durr A, Bonifati V, et al. Association between early-onset Parkinson's disease and mutations in the parkin gene. N Engl J Med 2000;342:1560-1567.
5. Trinh J, Farrer M. Advances in the genetics of Parkinson disease. Nat Rev Neurol 2013;9:445-454.
6. Sian-Hulsmann J, Mandel S, Youdim MB, Riederer P. The relevance of iron in the pathogenesis of Parkinson's disease. J Neurochem 2011;118:939-957.
7. Ordidge RJ, Gorell JM, Deniau JC, Knight RA, Helpern JA. Assessment of relative brain iron concentrations using T2-weighted and T2*-weighted MRI at 3 Tesla. Magn Reson Med 1994;32:335-341.
8. Haacke EM, Cheng NY, House MJ, et al. Imaging iron stores in the brain using magnetic resonance imaging. Magn Reson Imaging 2005;23:1-25.
9. Lotfipour AK, Wharton S, Schwarz ST, et al. High resolution magnetic susceptibility mapping of the substantia nigra in Parkinson's disease. J Magn Reson Imaging 2012;35:48-55.
10. Hardy PA, Gash D, Yokel R, Andersen A, Ai Y, Zhang Z. Correlation of R2 with total iron concentration in the brains of rhesus monkeys. J Magn Reson Imaging 2005;21:118-127.
11. Langkammer C, Krebs N, Goessler W, et al. Quantitative MR imaging of brain iron: a postmortem validation study. Radiology 2010;257:455-462.
12. Graham JM, Paley MN, Grunewald RA, Hoggard N, Griffiths PD. Brain iron deposition in Parkinson's disease imaged using the PRIME magnetic resonance sequence. Brain 2000;123:2423-2431.
13. Martin WR, Wieler M, Gee M. Midbrain iron content in early Parkinson disease: a potential biomarker of disease status. Neurology 2008;70:1411-1417.
14. Baudrexel S, Nurnberger L, Rub U, et al. Quantitative mapping of T1 and T2* discloses nigral and brainstem pathology in early Parkinson's disease. Neuroimage 2010;51:512-520.
15. Peran P, Cherubini A, Assogna F, et al. Magnetic resonance imaging markers of Parkinson's disease nigrostriatal signature. Brain 2010;133:3423-3433.
16. Du G, Lewis MM, Styner M, et al. Combined R2* and diffusion tensor imaging changes in the substantia nigra in Parkinson's disease. Mov Disord 2011;26:1627-1632.
17. Wang Y, Butros SR, Shuai X, et al. Different iron-deposition patterns of multiple system atrophy with predominant parkinsonism and idiopathetic Parkinson diseases demonstrated by phase-corrected susceptibility-weighted imaging. AJNR Am J Neuroradiol 2012;33:266-273.
18. van der Vegt JP, van Nuenen BF, Bloem BR, Klein C, Siebner HR. Imaging the impact of genes on Parkinson's disease. Neuroscience 2009;164:191-204.
19. Brockmann K, Groger A, Di Santo A, et al. Clinical and brain imaging characteristics in leucine-rich repeat kinase 2-associated PD and asymptomatic mutation carriers. Mov Disord 2011;26:2335-2342.
20. Berg D, Roggendorf W, Schroder U, et al. Echogenicity of the substantia nigra: association with increased iron content and marker for susceptibility to nigrostriatal injury. Arch Neurol 2002;59:999-1005.
21. Berg D, Schweitzer KJ, Leitner P, et al. Type and frequency of mutations in the LRRK2 gene in familial and sporadic Parkinson's disease*. Brain 2005;128:3000-3011.
22. Bruggemann N, Hagenah J, Stanley K, et al. Substantia nigra hyperechogenicity with LRRK2 G2019S mutations. Mov Disord 2011;26:885-888.
23. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
24. Lehericy S, Bardinet E, Poupon C, Vidailhet M, Francois C. 7 Tesla magnetic resonance imaging: a closer look at substantia nigra anatomy in Parkinson's disease. Mov Disord 2014;29:1574-1581.
25. Marrakchi-Kacem L, Delmaire C, Tucholka A, et al. Analysis of the striato-thalamo-cortical connectivity on the cortical surface to infer biomarkers of Huntington's disease. Med Image Comput Comput Assist Interv 2010;13:217-224.
26. Ulla M, Bonny JM, Ouchchane L, Rieu I, Claise B, Durif F. Is R2* a new MRI biomarker for the progression of Parkinson's disease? A longitudinal follow-up. PLoS One 2013;8:e57904.
27. Hagenah JM, Konig IR, Becker B, et al. Substantia nigra hyperechogenicity correlates with clinical status and number of Parkin mutated alleles. J Neurol 2007;254:1407-1413.
28. Walter U, Klein C, Hilker R, Benecke R, Pramstaller PP, Dressler D. Brain parenchyma sonography detects preclinical parkinsonism. Mov Disord 2004;19:1445-1449.
29. Takanashi M, Mochizuki H, Yokomizo K, et al. Iron accumulation in the substantia nigra of autosomal recessive juvenile parkinsonism (ARJP). Parkinsonism Relat Disord 2001;7:311-314.
30. Schweitzer KJ, Brussel T, Leitner P, et al. Transcranial ultrasound in different monogenetic subtypes of Parkinson's disease. J Neurol 2007;254:613-616.
31. Binkofski F, Reetz K, Gaser C, et al. Morphometric fingerprint of asymptomatic Parkin and PINK1 mutation carriers in the basal ganglia. Neurology 2007;69:842-850.
32. Hilker R, Klein C, Ghaemi M, et al. Positron emission tomographic analysis of the nigrostriatal dopaminergic system in familial parkinsonism associated with mutations in the parkin gene. Ann Neurol 2001;49:367-376.
33. Khan NL, Horta W, Eunson L, et al. Parkin disease in a Brazilian kindred: Manifesting heterozygotes and clinical follow-up over 10 years. Mov Disord 2005;20:479-484.
34. Klein C, Lohmann-Hedrich K, Rogaeva E, Schlossmacher MG, Lang AE. Deciphering the role of heterozygous mutations in genes associated with parkinsonism. Lancet Neurol 2007;6:652-662.
35. Marsden CD. Parkinson's disease. Lancet 1990;335:948-952.
36. Gorell JM, Ordidge RJ, Brown GG, Deniau JC, Buderer NM, Helpern JA. Increased iron-related MRI contrast in the substantia nigra in Parkinson's disease. Neurology 1995;45:1138-1143.
37. Reetz K, Gaser C, Klein C, et al. Structural findings in the basal ganglia in genetically determined and idiopathic Parkinson's disease. Mov Disord 2009;24:99-103.
38. Jellinger KA, Kienzl E, Rumpelmaier G, et al. Iron and ferritin in substantia nigra in Parkinson's disease. Adv Neurol 1993;60:267-272.
39. Faucheux BA, Martin ME, Beaumont C, Hauw JJ, Agid Y, Hirsch EC. Neuromelanin associated redox-active iron is increased in the substantia nigra of patients with Parkinson's disease. J Neurochem 2003;86:1142-1148.